Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
ex decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i ex » i e (Expand Search), i x (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
ex decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i ex » i e (Expand Search), i x (Expand Search)
-
1601
-
1602
-
1603
-
1604
-
1605
-
1606
-
1607
-
1608
-
1609
-
1610
-
1611
-
1612
-
1613
-
1614
Differential Inhibition of <i>Ex-Vivo</i> Tumor Kinase Activity by Vemurafenib in <i>BRAF</i>(V600E) and <i>BRAF</i> Wild-Type Metastatic Malignant Melanoma
Published 2013“…While basal phosphorylation profiles were similar in <i>BRAF</i> wild-type and <i>BRAF</i>(V600E) tumors, analysis with <i>ex-vivo</i> vemurafenib treatment identified a subset of 40 kinase substrates showing stronger inhibition in <i>BRAF</i>(V600E) tumor lysates, distinguishing the <i>BRAF</i> wild-type and <i>BRAF</i>(V600E) tumors. …”
-
1615
-
1616
-
1617
-
1618
-
1619
-
1620